Drug Profile
Research programme: pyrrolobenzodiazepine-based antibody drug conjugates - AstraZeneca/Tanabe Research Laboratories
Alternative Names: MEDI-0641Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator MedImmune; Tanabe Research Laboratories USA
- Developer AstraZeneca; Tanabe Research Laboratories USA
- Class Antibodies; Benzodiazepines; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 05 Apr 2017 Preclinical trials in Cancer in USA (unspecified route)
- 05 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)